Related Experiment Video

Updated: Jun 24, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Physical activity, high-density lipoprotein cholesterol subfractions and lecithin:cholesterol acyltransferase in

Reika Masuda1, Hiroyuki Imamura, Keiko Mizuuchi

  • 1Laboratory of Nutrition and Exercise Physiology, Nakamura Gakuen University Graduate School, 5-7-1 Befu, Jonan-ku, Fukuoka, Japan.

Nephron. Clinical Practice
|March 19, 2009
PubMed

Insights

Physical activity is linked to higher levels of HDL-C subfractions and Apo A-I in hemodialysis patients compared to peritoneal dialysis patients. This suggests a more pronounced association in hemodialysis patients.

Area of Science:

  • Nephrology
  • Cardiovascular Health
  • Biochemistry

Background:

  • Low high-density lipoprotein cholesterol (HDL-C) is a risk factor for atherosclerotic heart disease.
  • Mechanisms of HDL-C abnormalities in dialysis patients (hemodialysis/HD and peritoneal dialysis/PD) are not fully understood.

Purpose of the Study:

  • To investigate the relationship between physical activity and HDL-C subfractions (HDL(2)-C, HDL(3)-C) and lecithin:cholesterol acyltransferase activity.
  • To compare these relationships in HD and PD patients.

Main Methods:

  • Studied 35 HD and 26 PD patients.
  • Physical activity assessed by average daily steps over 7 days (steps/day).
  • Stepwise multiple regression analysis used.

Main Results:

  • In HD patients, steps/day positively correlated with HDL(2)-C and apolipoprotein (Apo) A-I.
  • In PD patients, steps/day positively correlated with HDL(3)-C.
  • HD patients in the highest physical activity group had significantly higher HDL(2)-C and Apo A-I than the lowest group; this was not seen in PD patients.

Conclusions:

  • Associations between physical activity, HDL-C subfractions, and Apo A-I are more pronounced in HD patients than PD patients.
  • Physical activity may play a differential role in modulating HDL-C metabolism in different dialysis modalities.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...